In vivo assays and models for COVID-19 drug development

47 - mouse tests

Service description

The set of in vivo tests that may be required for the development of a therapeutic molecule for the treatment of COVID-19.

SARS-CoV-2 specific models have been developed and are made available for the development of antiviral drugs: 

In vivo models:

  • Efficacity of coumpound in a SARS-CoV-2 model (study of survival and quantification of viral load)
    • K18-hACE2 mouse model 
    • Non human primate: cynomolgus macaque
    • Golden syrian hamster
    • Pulmonary fibrosis model (COVID-19 patients may progress to Acute Respiratory Distress Syndrome, of which a subset of survivors will develops lung fibrosis)
       
    This service is designed for Biotech companies developing SARS-CoV-2 new drugs.

Materials to provide

  • Details about the request
  • Compounds or library to test

    Further details on the project may be requested.

You will be able to exchange directly with the experts after filling in the form below.

Typical deliverables

  • Antiviral activity testing of any type of drugs (biological or small molecule)
  • Study following the specifications validated with the Expert

Get started with your COVID-19 in vivo assay request

Please answer the fields below to be contacted by our team of scientists

section1-3
Back
home